Reimagining health care, together Research & Evaluation Comagine Health collaborates with academic, government, and nonprofit partners to conduct research and evaluation studies designed to inform program, community, and policy improvements The Comagine Health Research and Evaluation Team was established in 2012 with a mission to bridge the research-to-practice gap and advance studies that promote health and wellbeing in the context of communities’ unique needs and challenges Our area of study • Substance use disorder prevention, • • • treatment and recovery Health care systems and practice change interventions Harm reduction and overdose and infectious disease prevention Epidemiology, community health and social determinants comagine.org We prioritize community-responsive and collaborative study designs We bring to our study partnerships • Strong relationships with health systems, clinics and • • community-based organizations Versatile team skills and flexible staffing to adapt to evolving study needs Ability to expand partners’ capacity, reach, dissemination and impact What services we provide? • Research and evaluation design and implementation, including • • • • • • • • • • • study management Collaborative proposal development Program, practice, and policy evaluation Provider, patient, and community intervention testing Readiness and needs assessments Study participant recruitment and retention Survey development and testing Qualitative and quantitative data collection and analysis Aggregation, cleaning, and management of large, linked datasets Epidemiological surveillance Policy and issue brief development Translation of findings for dissemination to broad audiences Who is on the team? What are we currently working on? Intervention to Increase Naloxone Engagement and Distribution in Community Pharmacies In partnership with Brandeis University and Oregon State University Supported by National Institute on Drug Abuse Novel Medicaid Policy to Reduce Opioids for Back Pain In partnership with Oregon Health & Science University, Oregon State University Supported by National Institute on Drug Abuse Determining Early Predictors of Opioid Overdose Using a Linked Dataset In partnership with Brigham and Women’s Hospital, McLean Hospital and Brandeis University Supported by National Institute on Drug Abuse Oregon HIV/HCV and Opioid Prevention and Engagement (OR-HOPE) In partnership with Oregon Health & Science University, Oregon Health Authority, Bay Area First Step and HIV Alliance Supported by National Institute on Drug Abuse, Centers for Disease Control and Prevention and Substance Abuse and Mental Health Services Administration Christi Hildebran, LMSW, CADC III Senior Director, Research and Evaluation Gillian Leichtling Director, Research and Evaluation Erin Stack, MS Research Manager Sara Hallvik, MPH VP, Analytic Services Sanae El Ibrahimi, PhD, MPH Biostatistician Mary Gray, PhD Senior Research Scientist Michelle Hendricks, PhD Senior Research Scientist Kate LaForge, MPH Research Associate II Sara Magnusson, MPH Research Associate II Danielle Good, PhD Research Associate II Soomin Shin, MA Research Associate I Justine Pope, MPH Research Associate I Overdose Data to Action Evaluation of Oregon’s Overdose Prevention Initiative In partnership with Oregon Health Authority Injury Violence and Prevention Program Supported by Centers for Disease Control and Prevention Kyn Kappesser, MSW Research Coordinator Oregon Measure 110 Process Evaluation In partnership with Arnold Ventures and RTI International Supported by Chan Zuckerberg Initiative Diana Flores, BS Research Coordinator comagine.org Reducing Overdose after Release from Incarceration (ROAR) In partnership with Oregon Health & Science University, Oregon State University, Oregon Department of Corrections, Bridgeway Recovery Services and CODA, Inc Supported by Centers for Disease Control and Prevention Peer Recovery Initiated in Medical Establishments + Infectious Disease Testing and Linkage to Care (PRIME+) In partnership with Oregon Health Authority Health Systems Division and Acute and Communicable Disease Program Supported by Centers for Disease Control and Prevention 080321